Novel Approaches Towards Cancer Therapy: Modified Concept for Autologous Tumour Cell Vaccination and Capsoid-Based Delivery of Tumour Antigens

By Dr Jürgen Hess, Head of Scientific Affairs, and Dr Christian Reiser, Managing Director at responsif GmbH Germany
Dr Jürgen Hess is Head of Scientific Affairs at responsif GmbH. He studied Biology in Wмrzburg, Germany and completed his PhD thesis in Microbiology. Following this he moved to the Sandoz Research Institute in Vienna, Austria, working on the functions of HIV-Nef. Dr Hess continued his research career at the Department of Immunology at Ulm, Germany and at the Max-Planck-Institute for Infection Biology, Berlin, Germany, where his work was focused on vaccination approaches leading to cell-mediated immunity against bacterial infections. He previously held a position as Chief Scientific Officer at november AG working on R&D projects in the field of immunotherapeutics.

Dr Christian Reiser is the Managing Director and one of the founders of responsif GmbH. He studied Chemistry at the University of Bayreuth in Germany and obtained his PhD in Biochemistry. During his scientific career he has specialised in protein chemistry and structural biology. Dr Reiser spent several years as a postdoctoral fellow at the Department of Medicine IV at the University Erlangen-Nuremberg where he worked on signalling pathways relating to renal pathology. In 1998, he joined november AG as a Project Manager, building up the molecular therapy department of november AG. Since 2002, he has been Vice President Operations and QA/QC of november AG.